Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Merck & Co Inc (NYSE:MRK) reported better-than-expected second-quarter earnings and sales results on Tuesday.
The company posted quarterly sales of $16.1 billion, up 7% year-over-year, beating the consensus estimate of $15.84 billion. Excluding the impact of foreign exchange, sales increased 11%. Merck reported adjusted EPS of $2.28, a shift from an EPS loss of $(2.06), beating the consensus of $2.15.
Merck revised and narrowed its full-year 2024 forecasts. The company expects 2024 sales of $63.4 billion—$64.4 billion, compared to previous guidance of $63.1 billion—$64.3 billion and the consensus of $64.34 billion.
The U.S. pharma giant expects 2024 adjusted EPS of $7.94 to $8.04, compared to prior guidance of $8.53-$8.65 and consensus of $8.16. The outlook includes one-time charges of $0.77 per share For Harpoon and Eyebio acquisitions.
Merck shares fell 1.6% to trade at $113.37 on Wednesday.
These analysts made changes to their price targets on Merck following earnings announcement.
Read Next:
Posted In: MRK